| % gASCA + | % ALCA + | % AMCA + | % ACCA + | % Omp + | |
| IBD patients | 529/1163 (45%) | 339/1163 (29%) | 503/1163 (43%) | 331/1163 (28%) | 311/1163 (27%) |
| Crohn’s disease | 499/874 (57%) | 304/874 (35%) | 403/874 (46%) | 263/874 (30%) | 251/874 (29%) |
| Ulcerative colitis | 25/259 (10%) | 31/259 (12%) | 85/259 (33%) | 63/259 (24%) | 51/259 (20%) |
| Indeterminate colitis | 5/30 (17%) | 4/30 (13%) | 15/30 (50%) | 5/30 (17%) | 9/30 (30%) |
| Controls | 4/312 (1%) | 10/312 (3%) | 64/312 (20%) | 82/312 (26%) | 41/312 (13%) |
| Inflammatory controls | 2/113 (2%) | 1/113 (1%) | 30/113 (27%) | 39/113 (35%) | 28/113 (25%) |
| Non-inflammatory controls | 2/199 (1%) | 9/199 (5%) | 34/199 (17%) | 43/199 (22%) | 13/199 (7%) |
ACCA, Anti-chitobioside antibodies; ALCA, anti-laminaribioside antibodies; AMCA, anti-mannobioside antibodies; gASCA, anti-S. cerevisiae antibodies; IBD, inflammatory bowel disease; Omp, outer membrane porin.